Literature DB >> 20813171

Levodopa analgesia in experimental neuropathic pain.

Nuria Cobacho1, José L De la Calle, José R González-Escalada, Carlos L Paíno.   

Abstract

Levodopa has been shown to produce analgesia in various clinical and experimental settings, but its use for chronic pain treatment has not been established. We have undertaken a study of the antiallodynic actions of levodopa in a rat model of painful mononeuropathy. When administered systemically, levodopa produced a decrease in tactile and cold allodynia lasting at least 3h. Direct intrathecal (i.t.) levodopa injection at lumbar levels produced a similar, though shorter, antiallodynic effect. This effect was blocked by the D2-type receptor antagonist sulpiride, which supports the involvement of the spinal dopaminergic system in the analgesic action of levodopa on neuropathic pain. These results provide experimental support on the antiallodynic effect of levodopa in neuropathic pain and suggest that at least part of the analgesic action takes place in the spinal cord and involves dopaminergic D2-type receptors. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813171     DOI: 10.1016/j.brainresbull.2010.08.012

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  10 in total

1.  The indirect pathway of the nucleus accumbens shell amplifies neuropathic pain.

Authors:  Wenjie Ren; Maria Virginia Centeno; Sara Berger; Ying Wu; Xiaodong Na; Xianguo Liu; Jyothisri Kondapalli; A Vania Apkarian; Marco Martina; D James Surmeier
Journal:  Nat Neurosci       Date:  2015-12-21       Impact factor: 24.884

2.  Presynaptic Inhibition of Primary Nociceptive Signals to Dorsal Horn Lamina I Neurons by Dopamine.

Authors:  Yong Lu; Maksym Doroshenko; Justas Lauzadis; Martha P Kanjiya; Mario J Rebecchi; Martin Kaczocha; Michelino Puopolo
Journal:  J Neurosci       Date:  2018-08-24       Impact factor: 6.167

3.  Dopamine modulation of transient receptor potential vanilloid type 1 (TRPV1) receptor in dorsal root ganglia neurons.

Authors:  Saikat Chakraborty; Mario Rebecchi; Martin Kaczocha; Michelino Puopolo
Journal:  J Physiol       Date:  2016-01-06       Impact factor: 5.182

4.  Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.

Authors:  G C Nascimento; K Bariotto-Dos-Santos; C R A Leite-Panissi; E A Del-Bel; M Bortolanza
Journal:  Neurotox Res       Date:  2018-04-02       Impact factor: 3.911

5.  D2 Receptors in the Periaqueductal Gray/Dorsal Raphe Modulate Peripheral Inflammatory Hyperalgesia via the Rostral Ventral Medulla.

Authors:  Luiz F Ferrari; JunZhu Pei; Michael Zickella; Charles Rey; Jacqueline Zickella; Anna Ramirez; Norman E Taylor
Journal:  Neuroscience       Date:  2021-04-04       Impact factor: 3.590

6.  Effect of Motor Impairment on Analgesic Efficacy of Dopamine D2/3 Receptors in a Rat Model of Neuropathy.

Authors:  Margarida Dourado; Helder Cardoso-Cruz; Clara Monteiro; Vasco Galhardo
Journal:  J Exp Neurosci       Date:  2016-04-06

7.  Anti-allodynic effects of levodopa in neuropathic rats.

Authors:  Hue Jung Park; Hwan Seok Joo; Young Hoon Kim; Ou-Kyoung Kwon; Jaemin Lee; Eun Sung Kim; Dong Eon Moon
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

Review 8.  Dorsal root ganglion neurons and tyrosine hydroxylase--an intriguing association with implications for sensation and pain.

Authors:  Pablo R Brumovsky
Journal:  Pain       Date:  2016-02       Impact factor: 7.926

9.  Lesion of the dopaminergic nigrostriatal pathway induces trigeminal dynamic mechanical allodynia.

Authors:  Wisam Dieb; Omar Ouachikh; Franck Durif; Aziz Hafidi
Journal:  Brain Behav       Date:  2014-02-20       Impact factor: 2.708

10.  Inhibition of tetrodotoxin-resistant sodium current in dorsal root ganglia neurons mediated by D1/D5 dopamine receptors.

Authors:  William Galbavy; Elham Safaie; Mario J Rebecchi; Michelino Puopolo
Journal:  Mol Pain       Date:  2013-11-28       Impact factor: 3.395

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.